ALK and neoplasm: In, 2018, the FDA approved Keytruda in combination with pemetrexed and platinum chemotherapy as the first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations, and in the same year, in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC (Table 2).